Toralizumab

Drug Profile

Toralizumab

Alternative Names: Anti-5c8 - IDEC; Anti-CD154 - IDEC; Anti-CD40L - IDEC; Anti-gp39 - IDEC; Anti-gp39 monoclonal antibody - IDEC; Anti-T-BAM - IDEC; Anti-TRAP - IDEC; E 6040; IDEC 131

Latest Information Update: 05 Jul 2007

Price : $50

At a glance

  • Originator IDEC Pharmaceuticals
  • Developer Eisai Co Ltd; IDEC Pharmaceuticals; Seikagaku Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Crohn's disease; Immune thrombocytopenic purpura; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 04 Aug 2004 Phase-I clinical trials in Autoimmune disorders in Japan (unspecified route)
  • 30 Apr 2003 IDEC Pharmaceutical is working with the FDA to remove the clinical hold status on IDEC 131
  • 09 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) was added to the adverse events section and the Skin therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top